Literature & Publications

Filter by Cateogory

Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus

2014

Kolodka T, Charles ML, Raghavan A, Radichev IA, Amatya C, et al. (2014) PLoS ONE 9(8): e103981. doi:10.1371/journal.pone.0103981

View Publication

Autoimmune Diabetes is Suppressed by Treatment with Recombinant Human Tissue Kallikrein-1

2014

Maneva-Radicheva L, Amatya C, Parker C, Ellefson J, Radichev I, et al. (2014). PLoS ONE 9(9): e107213. doi:10.1371/journal.pone.0107213

View Publication

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Tissue Kallikrein-1 (DM199) in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.

2014

ADA 74rd Scientific Sessions June, 2014

DM199: A Novel Form of Recombinant Human Tissue Kallikrein-1 for the Treatment of Diabetes Mellitus

2014

GTC Diabetes Summit April, 2014

Human Tissue Kallikrein (DM-199) Induces Diabetes-Protective Immunomodulation in NOD Mouse T1D Model

2013

ADA 73rd Scientific Sessions June, 2013

A Novel Bradykinin-2 Receptor Agonist Antibody that Improves Diabetic and Cardiovascular Endpoints

2012

American Heart Association Scientific Sessions November, 2012

A Novel Agonist Antibody to the Bradykinin 2 Receptor for the Treatment of Type 2 Diabetes

2012

ADA 72nd Scientific Sessions June, 2012

Human Tissue Kallikrein in treatment in the treatment of acute ischemic stroke

2019

Michelle Alexander-Curtis, Rick Pauls, Julie Chao, John J Volpi, Philip M Bath, and Todd A. Verdoorn

View Publication

Open-label study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease

2020

Thomas Marbury, Harry Alcorn, George Bakris, Maria Isabel Bermudez, Rajiv Agarwal, Charles Herzog, Glenn Chertow, George Canas

View Publication

Mechanism of Action

Genetically modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)

2018

Marina Devetzi, Maria Goulielmaki, Nicolas Khoury, Demetrios A. Spandidos, Georgia Sotiropoulou, Ioannis Christodoulou, and Vassilis Zoumpourlis

View Publication

Mechanism of Action

Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium

2007

Jane A. Mitchell Ferhana Ali Lucy Bailey Laura Moreno Louise S. Harrington

View Publication

Mechanism of Action

Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling

2007

Paolo Madeddu , Costanza Emanueli, Samir El-Dahr

View Publication

Mechanism of Action

Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing

2010

Julie Chao, Bo Shen, Lin Gao, Chun-Fang Xia , Grant Bledsoe, and Lee Chao1

1 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA

View Publication

Stroke and Stroke Recurrences

Human urinary kallindinogenase (KLK1) therapy for acute ischemic stroke: Clinical efficacy and risk factors

2019

Si‐Qia Chen, Dong‐Yang Mao, Dun‐Can Wei, Wen‐Zhen He

View Publication

Stroke and Stroke Recurrences

Efficacy and safety of human urinary kallidinogenase (KLK1) for acute ischemic stroke: a meta-analysis

2020

Yuanxiang Huang, Binglei Wang, Yue Zhang, Peize Wang, Xiangjian Zhang

View Publication

Stroke and Stroke Recurrences

Human Urinary Kallidinogenase decreases recurrent risk and promotes good recovery

2018

Dong Han, Xin Chen, Dongmei Li,  Shuang Liu, Yi Lyu, and Juan Feng

View Publication

Kidney Diseases

Exogenous kallikrein protects against diabetic nephropathy

2016

Wenjuan Liu 11, Yeping Yang 11, Yemei Liu 11, Xiaolan Lu, Shizhe Guo, Meng Wu, Meng Wang, Linling Yan, Qinghua Wang, Xiaolong Zhao, Xian Tong, Ji Hu, Yiming Li, Renming Hu, Robert C. Stanton, Zhaoyun Zhang

View Publication

Kidney Diseases

The Effect of Pancreatic Kininogenase (KLK1) Combined with Valsartan for the Treatment of Early DN

2013

Chin J Lab Diagn, December 2013, Vol 17, No. 12

Kidney Diseases

Clinical Efficacy of Pancreatic Kininogenase (KLK1) in the Treatment of Diabetic Nephropathy: A Systematic Evaluation

2014

Hainan Medical Journal, 2014-01

Stroke and Stroke Recurrences

Preclinical KLK1 Mechanism for AIS

2014

Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke

View Publication

Stroke and Stroke Recurrences

DM199/KLK1 for AIS Review Paper

2019

Human tissue kallikrein in the treatment of acute ischemic stroke

View Publication

Stroke and Stroke Recurrences

Urinary KLK1 after thrombolytic (tPA) treatment for acute cerebral infarction

2015

Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin, China

View Publication

Kidney Diseases

The kallikrein–kinin system in diabetic kidney disease

2017

Liu, Wenjuan; Stanton, Robert C.; Zhang, Zhaoyun

View Publication

Kidney Diseases

Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling

2007

Paolo Madeddu, Costanza Emanueli & Samir El-Dahr

View Publication